Microbicide Trials Network

MTN-020 - ASPIRE

ASPIRE - A Study to Prevent Infection with a Ring for Extended Use – was a Phase III safety and effectiveness trial of a vaginal ring containing the antiretroviral dapivirine that opened in August 2012 and enrolled 2,629 women at several sites in Africa. The dapivirine vaginal ring was developed by the International Partnership for Microbicides, which conducted another Phase III trial, The Ring Study, in parallel with ASPIRE.

 

Results

Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase III trial

22-February-2016

 

ASPIRE Q&A on Results

22-February-2016

 

ASPIRE Results At-A-Glance

22-February-2016

 

See Also:

Two Large Studies Show IPM’s Monthly Vaginal Ring Helps Protect Women Against HIV

22-February-2016

 

Sister Studies: The Ring Study and ASPIRE

22-February-2016

 

Other Study Milestones

Researchers complete ASPIRE Phase III trial of the dapivirine vaginal ring for HIV prevention in women; results are expected early 2016

29-June-2015

 

ASPIRE Phase III trial of a vaginal ring for HIV prevention completes enrollment of 2,629 women

26-June-2014

 

Phase III Trial of Dapivirine Ring Begins in Africa: ASPIRE testing new HIV prevention approach for women

24-July-2012

 

See Also

MTN-020 – ASPIRE Protocol